BAKER BROS. ADVISORS LP
13F Reported Value
ⓘ$20.0B
Holdings
84
Latest Filing
2026-06-30
Filing Quarter
Q2 2026
Portfolio Overview
BAKER BROS. ADVISORS LP disclosed 84 positions worth $20.0B in its Form 13F-HR for Q2 2026, led by $INCY (INCYTE CORP) at 17.5% of the equity portfolio, followed by $ONC and $RVMD. During the quarter the fund opened 8 new positions and exited 8 and a full exit from $ABVX. The portfolio is most concentrated in Healthcare (99.8% of disclosed assets). All figures are sourced directly from BAKER BROS. ADVISORS LP’s Form 13F-HR filing with the SEC under CIK 1263508.
AI Fund Analysis
Stable
$INCY
$ONC
$RVMD
$MDGL
$ACAD$INCY
$IDYA
$DSGN$RVMD
$INSMSector Allocation
AUM History
Top Equity Holdings by Value
Quarterly Activity — Q2 2026
Click any card to unlockTop Holdings
- 77.4#67
Quality
$3.5B30,762,330 sh - —
Quality
$2.5B8,801,567 sh - —
Quality
$2.1B11,443,357 sh - 40.7
Quality
$1.2B2,143,131 sh - 67.8
Quality
$1.1B42,912,904 sh - 28.4
Quality
$992.7M8,657,242 sh - 39.4
Quality
$937.8M8,796,111 sh - —
Quality
$828.2M7,915,792 sh - —
Quality
$776.1M19,919,186 sh - 33.9
Quality
$622.3M5,604,483 sh
| Company | Quality | Value | Shares |
|---|---|---|---|
| INCYTE CORP$INCY | 77.4#67 | $3.5B | 30,762,330 |
| BeOne Medicines Ltd.$ONC | — | $2.5B | 8,801,567 |
| Revolution Medicines, Inc.$RVMD | — | $2.1B | 11,443,357 |
| MADRIGAL PHARMACEUTICALS, INC.$MDGL | 40.7 | $1.2B | 2,143,131 |
| ACADIA PHARMACEUTICALS INC$ACAD | 67.8 | $1.1B | 42,912,904 |
 Kymera Therapeutics, Inc.$KYMR | 28.4 | $992.7M | 8,657,242 |
| INSMED Inc$INSM | 39.4 | $937.8M | 8,796,111 |
 Celcuity Inc.$CELC | — | $828.2M | 7,915,792 |
 Kodiak Sciences Inc.$KOD | — | $776.1M | 19,919,186 |
 RHYTHM PHARMACEUTICALS, INC.$RYTM | 33.9 | $622.3M | 5,604,483 |
Unlock AI quality scores for every holding
32-signal composite ranking on each of BAKER BROS. ADVISORS LP's 84 positions.
Showing top 10 of 84 holdings.
Sector Allocation
Healthcare
$19.9B
Other
$32.2M
Full Holdings — BAKER BROS. ADVISORS LP (Q2 2026)
All 84 disclosed positions from the latest Form 13F-HR, with quarter-over-quarter share changes and 13F Pro quality scores. Sourced from SEC EDGAR.
| # | Ticker | Company | Value | Weight | QoQ | Quality |
|---|---|---|---|---|---|---|
| 1 | $INCY | INCYTE CORP | $3.5B | 17.5% | +0% | 77.4 |
| 2 | $ONC | BeOne Medicines Ltd. | $2.5B | 12.6% | +0% | — |
| 3 | $RVMD | Revolution Medicines, Inc. | $2.1B | 10.7% | +20% | — |
| 4 | $MDGL | MADRIGAL PHARMACEUTICALS, INC. | $1.2B | 5.8% | +0% | 40.7 |
| 5 | $ACAD | ACADIA PHARMACEUTICALS INC | $1.1B | 5.4% | +0% | 67.8 |
| 6 | $KYMR | Kymera Therapeutics, Inc. | $992.7M | 5.0% | +0% | 28.4 |
| 7 | $INSM | INSMED Inc | $937.8M | 4.7% | +19% | 39.4 |
| 8 | $CELC | Celcuity Inc. | $828.2M | 4.2% | +0% | — |
| 9 | $KOD | Kodiak Sciences Inc. | $776.1M | 3.9% | +0% | — |
| 10 | $RYTM | RHYTHM PHARMACEUTICALS, INC. | $622.3M | 3.1% | +0% | 33.9 |
| 11 |  $PRAX | Praxis Precision Medicines, Inc. | $587.0M | 2.9% | +0% | — |
| 12 |  $ALKS | Alkermes plc. | $524.6M | 2.6% | +0% | — |
| 13 |  $SMMT | Summit Therapeutics Inc. | $477.7M | 2.4% | -10% | — |
| 14 |  $GRAL | GRAIL, Inc. | $275.0M | 1.4% | +0% | 31.6 |
| 15 |  $ABCL | AbCellera Biologics Inc. | $259.1M | 1.3% | +9% | 29.3 |
| 16 |  $IMVT | Immunovant, Inc. | $209.4M | 1.1% | -0% | — |
| 17 | $IDYA | IDEAYA Biosciences, Inc. | $186.7M | 0.9% | +27% | 36.1 |
| 18 |  $KNSA | Kiniksa Pharmaceuticals International, plc | $181.3M | 0.9% | +0% | — |
| 19 |  $ROIV | Roivant Sciences Ltd. | $166.9M | 0.8% | -3% | — |
| 20 |  $ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $162.4M | 0.8% | +0% | 38.7 |
| 21 |  $IONS | IONIS PHARMACEUTICALS INC | $162.4M | 0.8% | +0% | 23.4 |
| 22 |  $EWTX | Edgewise Therapeutics, Inc. | $150.4M | 0.8% | -44% | — |
| 23 |  $REPL | Replimune Group, Inc. | $122.3M | 0.6% | +0% | — |
| 24 |  $NRIX | Nurix Therapeutics, Inc. | $113.0M | 0.6% | +0% | 6.4 |
| 25 |  $STOK | Stoke Therapeutics, Inc. | $109.2M | 0.6% | +0% | 24.9 |
| 26 |  $GLUE | Monte Rosa Therapeutics, Inc. | $105.2M | 0.5% | +0% | 30.3 |
| 27 |  $IMTX | Immatics N.V. | $96.3M | 0.5% | -13% | — |
| 28 |  $DNLI | Denali Therapeutics Inc. | $96.0M | 0.5% | +0% | — |
| 29 |  $CRNX | Crinetics Pharmaceuticals, Inc. | $88.0M | 0.4% | +0% | 25.5 |
| 30 |  $DNTH | Dianthus Therapeutics, Inc. /DE/ | $83.1M | 0.4% | +0% | 22.6 |
| 31 |  $GPCR | Structure Therapeutics Inc. | $76.9M | 0.4% | +0% | — |
| 32 | $CELC | Celcuity Inc. | $69.2M | 0.3% | +0% | — |
| 33 |  $RAPP | Rapport Therapeutics, Inc. | $64.5M | 0.3% | +0% | — |
| 34 |  $ALMS | ALUMIS INC. | $56.6M | 0.3% | +0% | 7.1 |
| 35 |  $PRLD | Prelude Therapeutics Inc | $54.0M | 0.3% | +0% | 21.5 |
| 36 |  $RLAY | Relay Therapeutics, Inc. | $52.9M | 0.3% | +144% | 19.5 |
| 37 |  $MIRM | Mirum Pharmaceuticals, Inc. | $52.2M | 0.3% | +0% | 35 |
| 38 |  $BCYC | BICYCLE THERAPEUTICS PLC | $46.2M | 0.2% | +0% | — |
| 39 |  $ELVN | Enliven Therapeutics, Inc. | $45.9M | 0.2% | +0% | — |
| 40 |  $CLDX | Celldex Therapeutics, Inc. | $44.0M | 0.2% | +78% | 8.4 |
| 41 |  $VRDN | Viridian Therapeutics, Inc.\DE | $43.8M | 0.2% | +21% | 27.2 |
| 42 | $DSGN | Design Therapeutics, Inc. | $38.8M | 0.2% | +4% | — |
| 43 |  $TRDA | Entrada Therapeutics, Inc. | $37.3M | 0.2% | +0% | 7.3 |
| 44 | — | Faeth Therapeutics, Inc. - COM | $32.2M | 0.2% | NEW | — |
| 45 |  $AKTS | Aktis Oncology, Inc. | $32.1M | 0.2% | +0% | — |
| 46 |  $NGNE | Neurogene Inc. | $31.2M | 0.2% | +0% | 27.4 |
| 47 |  $JBIO | Jade Biosciences, Inc. | $27.3M | 0.1% | -25% | — |
| 48 |  $TSHA | Taysha Gene Therapies, Inc. | $27.3M | 0.1% | +0% | 4.9 |
| 49 |  $RCUS | Arcus Biosciences, Inc. | $26.0M | 0.1% | +103% | 8.5 |
| 50 |  $IRON | Disc Medicine, Inc. | $25.6M | 0.1% | +0% | — |
| 51 |  $ABSI | Absci Corp | $24.7M | 0.1% | +0% | 7 |
| 52 |  $GENB | Generate Biomedicines, Inc. | $24.0M | 0.1% | +0% | — |
| 53 |  $DBVT | DBV Technologies S.A. | $24.0M | 0.1% | +0% | — |
| 54 |  $XENE | Xenon Pharmaceuticals Inc. | $22.3M | 0.1% | +0% | 24 |
| 55 |  $TECX | Tectonic Therapeutic, Inc. | $20.9M | 0.1% | +0% | — |
| 56 |  $CERS | CERUS CORP | $18.7M | 0.1% | -36% | 38.5 |
| 57 |  $CTMX | CytomX Therapeutics, Inc. | $18.7M | 0.1% | +0% | 8.7 |
| 58 |  $DYN | Dyne Therapeutics, Inc. | $18.1M | 0.1% | +0% | — |
| 59 |  $CYTK | CYTOKINETICS INC | $18.0M | 0.1% | NEW | 28.1 |
| 60 |  $XNCR | Xencor Inc | $17.7M | 0.1% | +0% | 11.6 |
| 61 |  $SION | Sionna Therapeutics, Inc. | $17.6M | 0.1% | +0% | — |
| 62 |  $NTLA | Intellia Therapeutics, Inc. | $15.7M | 0.1% | NEW | 19.9 |
| 63 |  $PBLS | Parabilis Medicines, Inc. | $13.7M | 0.1% | NEW | — |
| 64 |  $MPLT | MapLight Therapeutics, Inc. | $13.1M | 0.1% | +0% | — |
| 65 |  $AVLN | Avalyn Pharma Inc. | $11.5M | 0.1% | NEW | — |
| 66 |  $EVMN | Evommune, Inc. | $11.3M | 0.1% | +0% | 14.9 |
| 67 |  $BNTX | BioNTech SE | $11.1M | 0.1% | +0% | — |
| 68 |  $TNGX | Tango Therapeutics, Inc. | $10.4M | 0.1% | NEW | 17.6 |
| 69 |  $AVTX | Avalo Therapeutics, Inc. | $10.2M | 0.1% | NEW | 11.7 |
| 70 |  $SERA | SERA PROGNOSTICS, INC. | $10.0M | 0.1% | +0% | 3.1 |
| 71 |  $VSTM | Verastem, Inc. | $9.5M | 0.1% | +327% | 29.7 |
| 72 |  $SGMT | Sagimet Biosciences Inc. | $7.4M | 0.0% | +0% | — |
| 73 |  $EIKN | Eikon Therapeutics, Inc. | $7.2M | 0.0% | +0% | — |
| 74 |  $LBRX | LB PHARMACEUTICALS INC | $6.5M | 0.0% | +0% | — |
| 75 |  $VTVT | vTv Therapeutics Inc. | $5.6M | 0.0% | +0% | — |
| 76 |  $WVE | Wave Life Sciences, Inc. | $4.8M | 0.0% | +0% | 7.5 |
| 77 |  $TARA | Protara Therapeutics, Inc. | $3.7M | 0.0% | +0% | — |
| 78 |  $TCRX | TScan Therapeutics, Inc. | $2.7M | 0.0% | +0% | 13.9 |
| 79 |  $IMNM | Immunome Inc. | $1.2M | 0.0% | NEW | 25.3 |
| 80 |  $SKYE | Skye Bioscience, Inc. | $1.1M | 0.0% | +0% | — |
| 81 |  $SANA | Sana Biotechnology, Inc. | $1.1M | 0.0% | +0% | — |
| 82 |  $ALGS | Aligos Therapeutics, Inc. | $479,227 | 0.0% | +0% | — |
| 83 |  $TYRA | Tyra Biosciences, Inc. | $338,788 | 0.0% | +0% | — |
| 84 |  $SRZN | Surrozen, Inc./DE | $13,750 | 0.0% | +0% | — |
New Positions (8)
Browse Top Institutional Investors
13F Pro tracks 8,700+ institutional investors filing 13F reports with the SEC.
to search all 8,700+ institutional filers.
Available Analysis
13F Pro tracks comprehensive institutional data for BAKER BROS. ADVISORS LP including:
Track BAKER BROS. ADVISORS LP's Full Portfolio
See every holding, quarter-over-quarter changes, sector allocation, and accumulation patterns for BAKER BROS. ADVISORS LP and 8,700+ other institutional investors.
Free tier includes full 13F search and fund profiles. Pro starts at $6.67/mo (billed annually).
AI-Powered Hedge Fund Analysis: BAKER BROS. ADVISORS LP
13F Pro is an AI hedge fund tracker and stock research platform. For BAKER BROS. ADVISORS LP (SEC CIK: 1263508), the platform ingests every quarterly Form 13F filing and applies AI-powered analysis on top — 10 specialized AI analysts (value, growth, momentum, macro, activist, and more) debate the fund's top positions and publish AI-generated analysis with cited SEC sources.
Every holding in BAKER BROS. ADVISORS LP's portfolio is scored on a 32-signal AI quality ranking (ROIC, FCF margin, revenue growth, institutional flow, earnings quality, shareholder dilution, and more). Track accumulation and distribution quarter over quarter, identify conviction positions, and see AI stock analysis for each position — alongside 8,700+ other institutional filers and 2,800+ AI-ranked companies.